



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/539,031	06/13/2005	Rajagopal Bakthavatchalam	60425(72021)	2029
21874	7590	01/07/2008	EXAMINER	
EDWARDS ANGELL PALMER & DODGE LLP			RAHMANI, NILOOFAR	
P.O. BOX 55874			ART UNIT	PAPER NUMBER
BOSTON, MA 02205			1625	
			MAIL DATE	DELIVERY MODE
			01/07/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/539,031	BAKTHAVATCHALAM ET AL.
	Examiner	Art Unit
	Niloofer Rahmani	1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 18 October 2007.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-3, 8-27,30-31,33,41-42,45,49,56-58 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-3,8-27,30-31,33,41-42,45,49,56-58 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

1. Claims 1-3, 8-27, 30-31, 33, 41-42, 45, 49, and 56-58 are pending in the instant application and claims 4-7, 28-29, 32, 34-40, and 43-44, 46-48, 50-55, and 59-73 are cancelled.

2. ***Priority***

This application was filed on 06/13/2005, which is a 371 of PCT/US03/39607, filed on 12/12/2003, which claims benefit of 60/433,139, filed on 12/13/2002.

3. The rejection of claims 1-3, 8-18 under 35 U.S.C. 102(b) over US 6,225,318, WO 01/25218, GB 2345486, WO 99/35146, WO 99/01441, WO 98/02434, WO 97/30044, US 5,580,870, US 5,616,582, US 5,063,227 is withdrawn in applicant's argument and amendment on dated 10/18/2007.

4. The rejection of claims 33, 41-42, 45, 49, 56-58 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is maintained. Applicants pointed out that efficacy in relevant animal models has in fact, been confirmed for VR1 antagonists. Applicants submitted some references to describe animal models for certain claimed therapeutic indications. It is examiner's position that applicants has examples of Capsaicin receptor binding assay, calcium mobilization assay, MDCK toxicity assay, Dorsal root ganglion cell assay. However, application has not guidance or examples for treating any diseases using the compounds in claim 1.

5. The rejection of claims 1-3,8-27,30-31, 41-42, 45,49, and 56-58

over US 2007/0105865, US 2004/0156869, US 2005/0215575, US

7,074,799 under Obvious-Type Double Patenting is maintained.

Applicants will consider filing a Terminal Disclaimer, if necessary and appropriate, to overcome these rejections upon indication that the present application is otherwise in condition for allowance.

6. ***New Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-3, 8-27, 30-31, 33, 41-42, 45, 49, and 56-58 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-3, 8-27, 30-31, 33, 41-42, 45, 49, and 56-58 are rejected because the term "hydrate thereof" is confusing. What does it mean by them? It is recommended to correct to hydrate thereof.

7. ***New Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3, 8-27, 30-31, 33, 41-42, 45, 49, and 56-58 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 1-3, 8-27, 30-31, 33, 41-42, 45, 49, and 56-58 lacks description of the claims i.e. " hydrate thereof". Hydrate is unpredictable because there are different hydrates. There are $\frac{1}{2}$ hydrate, 3 hydrates, or $\frac{3}{4}$ hydrate, etc. Therefore, the specification lacks description of "hydrate thereof".

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the

mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

NILOOFAR RAHMANI



MARGARET D. SEAMAN

12/20 /2007



PRIMARY EXAMINER

GROUP 1625